Literature DB >> 22240033

Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza.

Emili Diaz1, Ignacio Martin-Loeches, Laura Canadell, Loreto Vidaur, David Suarez, Lorenzo Socias, Angel Estella, Bernardo Gil Rueda, José Eugenio Guerrero, Montserrat Valverdú-Vidal, Juan Carlos Vergara, María Jesús López-Pueyo, Mónica Magret, Teresa Recio, Diego López, Jordi Rello, Alejandro Rodriguez.   

Abstract

OBJECTIVE: During the first pandemic, some patients with pandemic (H1N1) 2009 influenza were treated with corticosteroids. The objective of this study was to assess the effect on survival of corticosteroid therapy in patients with pandemic (H1N1) 2009 influenza.
METHODS: Prospective, observational, multicenter study performed in 148 ICU. Data were recorded in the GTEI/SEMICYUC registry. Adult patients with pandemic (H1N1) 2009 influenza confirmed by rt-PCR were included in the analysis. Database records specified corticosteroid type and reason for corticosteroid treatment.
RESULTS: 372 patients with the diagnosis of primary viral pneumonia and completed outcomes treated in an ICU were included in the database. Mechanical ventilation was used in 70.2% of the patients. 136 (36.6%) patients received corticosteroids after a diagnosis of primary viral pneumonia. Obesity (35.6% vs 47.8% p = 0.021) and asthma (7.6% vs 15.4% p = 0.018), were more frequent in the group treated with corticosteroids. A Cox regression analysis adjusted for severity and potential confounding factors found that the use of corticosteroid therapy was not significantly associated with mortality (HR = 1.06, 95% CI 0.626-1.801; p = 0.825).
CONCLUSIONS: Corticosteroid therapy in a selected group of patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza does not improve survival.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22240033     DOI: 10.1016/j.jinf.2011.12.010

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  31 in total

Review 1.  Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

Authors:  Zhengtu Li; Li Li; Shuai Zhao; Jing Li; Hongxia Zhou; Yunhui Zhang; Zifeng Yang; Bing Yuan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  A retrospective evaluation of critically ill patients infected with H1N1 influenza A virus in Bursa, Turkey, during the 2009-2010 pandemic.

Authors:  Kelebek Girgin Nermin; Iscimen Remzi; Akogul Zeynep; Cimen Ilker; Oner Torlar Meltem; Ozkaya Guven; Kahveci Ferda; Akalin Halis
Journal:  Afr Health Sci       Date:  2015-06       Impact factor: 0.927

Review 3.  Corticosteroids for severe influenza pneumonia: A critical appraisal.

Authors:  Wagner Luis Nedel; David Garcia Nora; Jorge Ibrain Figueira Salluh; Thiago Lisboa; Pedro Póvoa
Journal:  World J Crit Care Med       Date:  2016-02-04

4.  Activation of A1-adenosine receptors promotes leukocyte recruitment to the lung and attenuates acute lung injury in mice infected with influenza A/WSN/33 (H1N1) virus.

Authors:  Famke Aeffner; Parker S Woods; Ian C Davis
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

5.  Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome.

Authors:  Michael A Matthay; Katherine D Wick
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

6.  Corticosteroids as adjunctive therapy in the treatment of influenza.

Authors:  Louise Lansbury; Chamira Rodrigo; Jo Leonardi-Bee; Jonathan Nguyen-Van-Tam; Wei Shen Lim
Journal:  Cochrane Database Syst Rev       Date:  2019-02-24

7.  Fatal Fulminant Pneumonia Caused by Methicillin-Sensitive Staphylococcus aureus Negative for Major High-Virulence Factors Following Influenza B Virus Infection.

Authors:  Katsunori Masaki; Makoto Ishii; Masaki Anraku; Ho Namkoong; Ryo Miyakawa; Takeshi Nakajima; Koichi Fukunaga; Katsuhiko Naoki; Sadatomo Tasaka; Kenzo Soejima; Koichi Sayama; Kayoko Sugita; Satoshi Iwata; Longzhu Cui; Hideaki Hanaki; Naoki Hasegawa; Tomoko Betsuyaku
Journal:  Am J Case Rep       Date:  2015-07-14

8.  2009 pandemic H1N1 influenza virus elicits similar clinical course but differential host transcriptional response in mouse, macaque, and swine infection models.

Authors:  Jennifer T Go; Sarah E Belisle; Nicolas Tchitchek; Terrence M Tumpey; Wenjun Ma; Juergen A Richt; David Safronetz; Heinz Feldmann; Michael G Katze
Journal:  BMC Genomics       Date:  2012-11-15       Impact factor: 3.969

9.  Prevention of Influenza Virus-Induced Immunopathology by TGF-β Produced during Allergic Asthma.

Authors:  Yoichi Furuya; Andrea K M Furuya; Sean Roberts; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  PLoS Pathog       Date:  2015-09-25       Impact factor: 6.823

10.  Severe influenza treatment guideline.

Authors:  Won Suk Choi; Ji Hyeon Baek; Yu Bin Seo; Sae Yoon Kee; Hye Won Jeong; Hee Young Lee; Byung Wook Eun; Eun Ju Choo; Jacob Lee; Young Keun Kim; Joon Young Song; Seong-Heon Wie; Jin Soo Lee; Hee Jin Cheong; Woo Joo Kim
Journal:  Korean J Intern Med       Date:  2014-01-02       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.